Goldman Sachs Cuts SUNEVISION Target Price to HK$10, Maintains Buy Rating

Stock News
Sep 08

Goldman Sachs has reduced its target price for SUNEVISION (01686) from HK$10.9 to HK$10 while maintaining its "Buy" rating on the stock.

For the second half of fiscal year 2025, SUNEVISION reported EBITDA of HK$1.068 billion and earnings per share of HK$0.1217. The EBITDA came in 9% below Goldman Sachs' expectations, primarily due to revenue falling short of forecasts by 11%, though this was partially offset by EBITDA margin expansion of 2 percentage points. Depreciation and amortization were lower than expected, with an effective tax rate of approximately 15% compared to the firm's 16% forecast.

The company declared a final dividend of HK$0.12 per share, which was 13% below Goldman Sachs' expectations. The full-year dividend payout ratio stood at approximately 46%, lower than the firm's anticipated 50%. Management has reiterated that the dividend payout ratio ceiling will remain unchanged at 50%.

Goldman Sachs has revised down its revenue forecasts for fiscal years 2026 and 2027 by 11% and 13% respectively. Earnings per share estimates have also been reduced by 12% and 16% for the same periods. The firm expects the dividend payout ratio to remain at 46% for fiscal years 2026-28, compared to its previous expectation of 50%. Goldman Sachs projects fiscal year 2028 earnings per share and dividend per share at HK$0.37 and HK$0.17 respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10